Thrombocytosis disease
MONDO:0002249A disease characterized by higher than normal platelet counts in the peripheral blood.
Also known as: Platelet count increased, elevated Platelet count, thrombocytosis
101 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Blood clot risk in rare disease: could a higher dose of clopidogrel offer better protection?
Disease control Not yet recruitingThis study looks at whether a higher dose of the blood thinner clopidogrel works better for people with essential thrombocythemia (ET), a rare blood disorder that raises the risk of dangerous blood clots. The standard dose may not work well for many ET patients, so researchers wi…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for rare blood cancer: targeted drug enters final testing
Disease control Not yet recruitingThis study tests a new drug, INCA033989, against the best current treatments for people with a rare blood cancer called essential thrombocythemia who have a specific gene mutation (CALR). About 426 adults who have already tried at least one prior therapy will be randomly assigned…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New oral drug could tame overactive bone marrow in rare blood cancers
Disease control Not yet recruitingThis study tests a pill called selinexor in 15 adults with chronic blood cancers (MPN) whose blood cell counts are too high. The goal is to see if selinexor can safely bring those counts down and ease symptoms. Participants take the drug once a week for up to 3 months and are fol…
Phase: PHASE2 • Sponsor: Zhongshan Hospital (Xiamen), Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for rare blood cancers: interferon trial launches
Disease control Not yet recruitingThis phase 2 trial tests ropeginterferon alfa-2b, a long-acting immune protein, in 35 adults with rare blood cancers like CMML and MDS/MPN overlap syndromes. The drug aims to slow cancer cell growth by boosting the immune system. Researchers will check safety, best dose, and how …
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New CAR-T therapy targets antibodies blocking Life-Saving transplants
Disease control Not yet recruitingThis early-stage study tests a new treatment using special immune cells (CAR-T cells) designed to reduce harmful antibodies that can prevent or damage bone marrow transplants. About 18 people with blood diseases who have these antibodies will receive the cells in increasing doses…
Phase: PHASE1, PHASE2 • Sponsor: Chang Yingjun • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could a feeding tube after transplant save the gut?
Disease control Not yet recruitingThis study tests whether starting tube feeding right after a stem cell transplant can reduce severe gut graft-versus-host disease (GVHD) in people with blood cancers or disorders. About 112 participants will be randomly assigned to either standard care or early tube feeding. The …
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Personalized exercise shows promise for fatigue in rare blood cancers
Symptom relief Not yet recruitingThis study tests whether a 12-week personalized exercise program can reduce fatigue and improve physical function in people with myeloproliferative neoplasms (MPN) and chronic myeloid leukemia (CML). Participants will do supervised aerobic and resistance training twice a week plu…
Phase: NA • Sponsor: Carmen Fava • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
New app aims to boost wellness in blood cancer patients
Symptom relief Not yet recruitingThis study tests a digital app called WELL-MPN designed to help adults with myeloproliferative neoplasms (MPNs) improve their diet, physical activity, symptoms, and emotional well-being. About 75 participants will be randomly assigned to use the app or receive standard written li…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC